Why This Beaten-Down Marijuana Stock Might Still Be a Buy

Despite recent headwinds, Hexo Corp (TSX:HEXO)(NYSE:HEXO) is still worth considering; here is why.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Hexo (TSX:HEXO)(NYSE:HEXO) hasn’t escaped the recent struggles in the marijuana industry. The company has shed some 48% of its value since late April, as the largest pot firms were losing altitude with astonishing speed. However, much like other marijuana companies, there are reasons to be bullish on Hexo’s prospects. The pot grower recently got a nice boost in the form of an analyst recommendation, which helped Hexo’s stock pop by about 10% on Friday. Analyst recommendations aside, though, here is why Hexo is far from throwing in the towel in the vast and competitive marijuana sector.

Truss beverages 

Hexo made a lot of noise earlier in the year. The firm acquired another marijuana company by the name of Newstrike Brands for $263 million. One of the motivating factors behind this acquisition was the fact that it would help Hexo increase its peak production capacity to about 150,000 kg per year. Also, Hexo holds a leading share of the cannabis market in Quebec. This is due to the company signing a five-year preferred supplier agreement to supply a total of about 200,000 kg of pot over the five-year period. This deal is the largest such provincial agreement to date, and it tips the balance in Hexo’s favor.

Despite these encouraging signs, the best argument for why Hexo is still worth considering is its partnership with beverage maker Molson Coors Brewing. The two firms penned a deal to start a joint venture to produce and sell cannabis-infused drinks. This venture goes by the name of Truss Beverages, and it represents an opportunity for Hexo to significantly improve its financial results. After a long and arduous wait, the cannabis derivative market will finally open in Canada, which means pot companies will be able to benefit from several high-margin opportunities. Hexo has been preparing for this for months. Its partnership with a firm of the caliber of Molson Coors — with its expertise in the industry, its distribution network, and its deep pockets — puts the Quebec-based marijuana company ahead of most of its peers. 

It is important to note that Hexo will be competing with none other than Canopy Growth in this market. After all, Canopy also has a partnership with a beverage maker. However, Hexo is planning to seek other avenues for growth. For instance, the firm is looking to enter the edibles segment by making gummies available to its customers, as the company’s CEO noted in a recent earnings call. Finally, Hexo is looking to dip its toes in the lucrative vaping market, which has been gaining steam recently and promises to be one of the liveliest in the cannabis derivative market.

The bottom line

Hexo is well positioned to profit from the launch of derivative products in Canada, which makes the firm worth considering, despite its recent struggles. Of course, a lot can still go wrong, but for those willing to take a little risk, Hexo might be one of the better options in the marijuana sector. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of Molson Coors Brewing.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »